Enteric fever, caused by Salmonella enterica serovars Typhi and Paratyphi, remains a substantial cause of illness in low- and middle-income countries where routine blood culture surveillance is often unavailable. Azithromycin is an effective treatment for enteric fever and biannual mass drug administration (MDA) to young children has reduced all-cause mortality in parts of sub-Saharan Africa. However, the community-level impact of azithromycin MDA on enteric fever transmission and infection intensity was previously uncertain. The authors performed a secondary analysis of an existing randomized trial to evaluate whether five years of biannual azithromycin MDA modified enteric fever seroincidence in rural Niger.
This analysis used samples and data from the MORDOR trial (NCT02048007), a cluster-randomized, placebo-controlled study in 30 communities in the Dosso Region of Niger. Children aged 1–59 months received either biannual azithromycin or placebo as part of the trial intervention. Dried blood spots were collected at two time points relevant to this analysis: baseline in 2015 and Year 5 in 2020. A total of 1,417 children's samples were included in the serologic analysis: 423 from baseline and 994 from Year 5.
IgA and IgG responses to Hemolysin E were measured using a kinetic ELISA performed on dried blood spots. Hemolysin E antibody responses were used as markers of recent infection with S. Typhi/Paratyphi. Seroincidence—the estimated incidence of infection inferred from cross-sectional antibody measurements—was calculated using maximum likelihood methods. These estimates were derived by applying antibody kinetic parameters obtained from blood culture–confirmed enteric fever patients to the observed antibody distributions in the study population.
At baseline (2015) and Year 5 (2020), estimated seroincidence increased markedly in both study arms. In placebo communities, seroincidence rose from 68.5 (95% CI 58.0–80.7) to 145.2 (95% CI 132.3–159.3) per 100 person-years. In azithromycin-treated communities, seroincidence increased from 74.7 (95% CI 56.5–98.7) to 135.2 (95% CI 112.4–162.6) per 100 person-years.
The calculated difference-in-differences comparing the change over time between the azithromycin and placebo arms did not show a statistically significant reduction associated with azithromycin MDA (difference-in-differences −16.2; 95% CI −53.1 to 20.8). Thus, over the five-year period, biannual azithromycin MDA did not significantly lower community-level enteric fever seroincidence in the overall study population.
When stratified by age, children under 2 years showed a different pattern. The increase in estimated seroincidence from baseline to Year 5 was smaller in the azithromycin arm (37.5; 95% CI 1.3–73.6 per 100 person-years) than in the placebo arm (81.1; 95% CI 54.0–108.2 per 100 person-years). The difference-in-differences for this subgroup was −43.7 per 100 person-years with a reported 95% CI that approached but did not definitively exclude zero (95% CI −88.8 to −1.5 to 0.02 as reported). The authors interpret this as a potential attenuation of rising seroincidence among the youngest children in azithromycin-treated communities.
The analysis indicates that estimated community-level enteric fever seroincidence among young children in rural Niger was high at baseline and increased substantially over the five-year study period. Five years of biannual azithromycin MDA did not produce a statistically significant reduction in overall seroincidence, though a signal of possible effect was observed in children under 2 years.
The authors highlight two practical implications: first, the high and rising burden of enteric fever supports Niger's recent introduction of typhoid conjugate vaccine; second, antibody-based serosurveillance can provide a useful approach to monitor enteric fever infection intensity in settings lacking blood culture surveillance.
This report is a secondary analysis of the MORDOR randomized trial (ClinicalTrials.gov NCT02048007). It is presented as a medRxiv preprint and has not been peer reviewed; the authors state no competing interests. De-identified data will be made available on OSF upon publication. The methods rely on antibody kinetics calibrated to blood culture–confirmed cases; details of those kinetic parameters and any assumptions are described in the primary methods but are not repeated in full in this summary. The source article reports trial ethical approvals from the University of California, San Francisco and the Niger Ministry of Health.
Overall, the findings document a substantial enteric fever infection burden in young Nigerien children and suggest that while biannual azithromycin MDA did not significantly lower overall seroincidence, it may have mitigated rising infection incidence in the youngest age group, reinforcing the role of vaccination and serologic monitoring in control strategies.